

7/PRTS

1

PREPARATION OF GLYCOSYLATED TUMOR NECROSIS FACTORField of the Invention

5 The present invention relates to glycosylated human tumor necrosis factor-alpha (TNF- $\alpha$ ), pharmaceutical composition containing it, and methods for its preparation and use.

Background of the Invention

10 Cytokines are polypeptide mediators secreted by cells that affect the function of other cells and which play an important role in the interactions between cells in the immune system. Together with other substances, cytokines constitute the molecular language of inflammation and immunity and form a complex of interacting and overlapping networks of signals that orchestrate the body's defensive reactions. One such cytokine is tumor necrosis factor (TNF).

15 TNF is one of a family of proteins that orchestrate the body's remarkably complex response to injury and infection. TNF is implicated in a wide variety of human diseases, may be effective against certain cancers, plays a role in septic shock and cachexia, is a mediator of inflammation in various immunological reactions, and also seems to be important in some pathological effects seen in malaria and meningococcal septicemia. With tumor necrosis factor, as with many other factors produced by the body, there seems to be a fine line between benefit and harm: an agent that is helpful in the local control of injury and infection may be toxic when it is released in large amounts or in the wrong place. See Old, "Tumor Necrosis Factor", Scientific American, 258:59-60, 69-75 (May 1988).

25 TNF exerts its effect by binding to specific receptors on cell membranes and causing clustering of the receptors. Two TNF receptors, with molecular weight of 55,000 Daltons and 75,000 Daltons, are known. After TNF binds to its receptor, the complex is internalized and degraded. Receptor clustering activates protein kinases

and phospholipases, leading to production of signal mediators and secondary messengers, resulting in cell death.

The TNF "family" includes two structurally and functionally related proteins, TNF-alpha and TNF-beta. The close relationship of these proteins was not known until 1984 when coding of the cDNAs for human TNF-alpha and TNF-beta, unexpectedly revealed that they are about 30% homologous at the amino acid level. Both TNF-alpha and TNF-beta bind to the same cell surface receptors, and they are very similar (though not identical) in the spectra of their activity. However, the regulation of expression of the TNF-alpha and the TNF-beta genes and the processing of the two corresponding proteins by the producing cells are completely different.

TNF- $\alpha$  has previously been referred to as cachectin and is produced primarily by mononuclear phagocytes, such as macrophages and monocytes. It is also produced by astrocytes, endothelial cells and some transformed cells. Mature human TNF-alpha is a polypeptide of 157 amino acid residues. The apparent molecular mass of human TNF-alpha is 17,000 Daltons. In its native form, TNF-alpha is a trimer. Among the indications for which TNF- $\alpha$  is known are melanoma, EL-4 lymphoma, Meth-A tumors, melanocytes, leukemia, carcinomas of the liver or lung, metastases or mammary carcinomas, cancers including breast, anal, colorectal, head, neck and other body organs. TNF has been found to have potential anti-microbial properties and is extremely potent against malarial and other parasites. TNF has been found to protect cells against some viral infections and prevent autoimmune diseases such as Type 1 diabetes. TNF inhibits lipid accumulation and alterations in adipose specific RNAs. TNF prevents the expression of genes responsible for producing enzymes important in storing fat. TNF exhibits a synergistic cytotoxic activity with interferon.

TNF-beta, also known as lymphotoxin and produced primarily by lymphocytes, contains 171 residues and has an apparent molecular mass of 25,000 Daltons. In addition to the 14 additional amino acids present at the amino terminus of TNF-beta, the difference in the size of the two molecules has been attributed to the absence of N-glycosylation in human TNF-alpha, as opposed to the presence of one

N-glycosylation site in TNF-beta. Vilcek et al, J.Biol.Chem. 266:7313-7316 (1991).

Although murine TNF-alpha is a glycoprotein, there is no evidence to suggest that human TNF-alpha is glycosylated. Indeed it is described in the literature as being non-glycosylated (Markham et al, Eur. Cytokine Netw., 6: 49-54 (1995); Fiers, FEBS letters, 285:199-212 (1991)).

Human TNF-alpha can be isolated from human cells or prepared by recombinant techniques. While, theoretically, human TNF-alpha can be prepared by recombinant methods using any type of cells, conventionally TNF-alpha is prepared using transfected *E. coli*, cf. Wallace et al., U.S. Patent No. 4,879,226 and Aggarwal et al., EP 0168214. In fact, Aggarwal et al. specifically state that cultures of cells derived from multicellular organisms may be used as hosts, but that this is not preferred because of the excellent results obtained with TNF expressing microbes.

Subtle differences have been found between native human TNF-alpha and recombinant human TNF-alpha. The isoelectric point of native TNF-alpha is 5.6 and that of recombinant human TNF-alpha prepared in *E. coli* is 5.3.

Korn et al, Lymphokine Res., 7:349-358 (1988), reports the production of TNF in eukaryotic Chinese hamster ovary (CHO) cells and states that the advantage of a eukaryotic expression vector is a reduction of problems with endotoxin contamination as endotoxin may precipitate septic shock. The specific means of isolating the TNF actually used in this publication involved immunoprecipitation of the culture supernatant with polyclonal rabbit anti-TNF antibody with the immunoprecipitated material being released from SEPHAROSE beads by boiling in sample buffer containing SDS and beta-mercaptoethanol and run on a 15% SDS-polyacrylamide gel for two hours at 30 mA. Such a treatment would cause substantial loss of the biological activity of the protein. Thus, the actual product of the Korn publication is denatured and is not an isolated biologically active glycosylated TNF. Furthermore, Korn et al never recognized that the TNF produced by that method was glycosylated.

Marmenout et al, Eur. J. Biochem, 152:512-522 (1985), discloses the recombinant expression of TNF cDNA in monkey COS cells. While this publication reports expression of TNF activity in the culture medium, there is no disclosure that TNF was ever separated from the medium in any way. Indeed, there is no disclosure that it was even subjected to SDS-PAGE chromatography. Marmenout states that the available data suggests that human TNF is not glycosylated. Because of the substantially greater expression achieved in *E. coli* than from the COS cells, the remaining work reported in the Marmenout publication was done with the *E. coli* expression product, which is necessarily non-glycosylated.

10                   Malik et al., in European Journal of Cancer, 26(1): 1031-1034 (1990), studied the action of TNF as a tumor-promoting agent by causing Chinese hamster ovary (CHO) cells to act as a tumor to demonstrate that TNF can stimulate tumor progression. In this case, the CHO cells transfected with the gene for human TNF were implanted directly into mice and the TNF produced by these cells was never isolated.

### Summary of the Invention

Pure recombinant human TNF-alpha has now been produced in Chinese hamster ovary (CHO) cells and purified to homogeneity. This purified TNF-alpha has 20 surprisingly been found to be glycosylated.

The pure recombinant human TNF-alpha produced in CHO cells was partially characterized by a variety of methods including capillary electrophoresis, carbohydrate composition, carbohydrate mapping, isoelectric focusing, SDS-PAGE, and RP-HPLC. These analyses indicated that recombinant human TNF-alpha produced in CHO cells was different from recombinant human TNF-alpha produced in 25 *E. coli*.

Although human TNF-alpha is described in the literature as a non-glycosylated protein, the recombinant human TNF-alpha obtained from CHO cells, according to the present invention was found to contain multiple charged species.

When digested by neuraminidase, an enzyme that cleaves sialic acid, CHO recombinant human TNF-alpha multiple charged species collapsed to one major isoform/charged form as determined by isoelectric focusing and capillary electrophoresis, indicating that the variability of isoforms/charged forms stems from 5 sialic acid and, hence, the molecule is glycosylated. Carbohydrate composition and mapping demonstrated the existence of O-glycosylation.

Neuraminidase and O-glycanase-digested CHO recombinant human TNF-alpha co-migrated with *E. coli* recombinant human TNF-alpha on SDS-PAGE, 10 isoelectric focusing gels, and co-eluted on the capillary electrophoresis and reverse phase-high performance liquid chromatography (RP-HPLC), indicating that both proteins are similar in their polypeptide core but differ in the presence of O-linked oligosaccharide in the CHO recombinant human TNF-alpha.

The glycosylated human recombinant TNF prepared according to the 15 present invention is particularly useful because, compared to non-glycosylated human TNF, the glycosylated TNF may have an increased half-life in body fluids, may improve binding to receptors, and may be better protected against the influence of proteases.

#### Brief Description of the Drawings

20 Figures 1A and 1B are oligomaps of CHO recombinant human TNF-alpha. Figure 1A shows the "O" mode, in which O-linked glycoside linkages are preferentially released, and Figure 1B shows the "N + O" mode, in which both N-linked and O-linked glycosidic linkages are released. The oligomaps indicate only the presence of one main O-linked oligoform.

25 Figures 2A-2E show capillary electrophoresis analysis of CHO recombinant human TNF-alpha. Figure 2A shows CHO recombinant h-TNF; Figure 2B shows CHO recombinant h-TNF plus neuraminidase; Figure 2C shows CHO recombinant h-TNF plus neuraminidase plus O-glycanase; Figure 2D shows CHO

recombinant h-TNF plus neuraminidase plus O-glycanase + N-glycanase. Figure 2E shows *E. coli* recombinant human TNF.

#### Detailed Description of the Invention

5 For the purpose of the present invention, tumor necrosis factor-alpha will be referred to as tumor necrosis factor or TNF and tumor necrosis factor-beta will be referred to as lymphotoxin.

In synthesizing glycosylated tumor necrosis factor, DNA which encodes tumor necrosis factor is ligated into a replicable (reproducible) vector, the vector used 10 to transform host CHO cells, the CHO host cells are cultured, and TNF is recovered from the culture medium. This general process is used to construct glycosylated human TNF. The tumor necrosis factor species which are capable of synthesis herein include mature (valyl amino-terminal) tumor necrosis factor, pre-tumor necrosis factor ("pre-TNF", defined herein), and derivatives of TNF including fusion proteins wherein 15 TNF (including mature tumor necrosis factor) is linked to other proteins or polypeptides by a peptide bond at the amino and/or carboxyl terminal amino acids to TNF. Human tumor necrosis factor synthesized in CHO recombinant culture is characterized by the presence of non-human cell components, including proteins, in amounts and of a character which are physiologically acceptable for administration to 20 patients in concert with the tumor necrosis factor. These components are generally present in innocuous contaminant quantities, on the order of less than 1 percent by weight. Further, CHO recombinant cell culture enables the production of tumor necrosis factor absolutely free of homologous proteins.

Homologous proteins are those which are normally associated with the 25 tumor necrosis factor as it is found in nature, e.g., in cells, cell exudates, or body fluids. For example, a homologous protein for human tumor necrosis factor is human serum albumin. Heterologous proteins are the converse, i.e., they are not naturally associated or found in combination with the tumor necrosis factor in question.

09/16/2015 10:25:02 AM

"Substantially homogeneous" glycosylated TNF means glycosylated TNF which is substantially free of other proteins native to the source from which the glycosylated TNF was isolated. This means that homogeneous glycosylated TNF is substantially free of blood plasma proteins such as albumin, fibrinogen, serine proteases, alpha- globulins, non-TNF cytotoxic polypeptides such as lymphotoxin or interferons, or other proteins of the cell or organism which serve as the synthetic origin of the glycosylated TNF, including whole cells and particulate cell debris.

Ordinarily, if a mammalian cell is transformed with (a) a vector containing the entire tumor necrosis factor structural gene (including a 5' start codon), or (b) the gene for mature tumor necrosis factor or a TNF derivative operably ligated to a secretory leader, which may also include the TNF secretory leader presequence, and the cell cultured, then mature TNF is recovered from the culture medium.

Similarly, if DNA which encodes TNF is operably ligated in a vector to a secretory leader which is properly processed by the host cell to be transformed, the host transformed with the vector and cultured then the tumor necrosis factor is synthesized without amino-terminal methionyl or blocked methionyl. Secretory leaders and host cells may be selected that also result in improper transport of mature protein into cell periplasm.

Once tumor necrosis factor is prepared by cell bioprocess, it generally is purified by recovering the supernatant culture fluid, removing solids, absorbing TNF from the supernatant admixture (containing TNF and other proteins) onto a hydrophobic substance, eluting TNF from the substance, adsorbing TNF onto a tertiary amino anion exchange resin, eluting TNF from the resin, adsorbing TNF onto an anion exchange resin (preferably quaternary amino-substituted) having substantially uniform particle size, and eluting TNF from the resin. The TNF composition can be optionally concentrated and purified by chromatofocusing at any point in the purification procedure, for example by isoelectric focusing or passage through a sieving gel such as SEPHADEX G-25.

The tumor necrosis factor obtained according to the present invention from transfected CHO cells is always obtained as a glycoprotein.

Purified glycosylated TNF from recombinant cell culture is combined for therapeutic use with pharmaceutically acceptable carriers and excipients, such as physiologically innocuous stabilizers and excipients, and prepared in dosage form as by lyophilization in dosage vials or storage in stabilized aqueous preparations. Alternatively, TNF may be incorporated into a polymer matrix for implantation into tumors or surgical sites from which tumors have been excised, thereby effecting a time-release of the tumor necrosis factor in a localized high gradient concentration.

10 In therapeutic applications, glycosylated TNF may be advantageously combined with predetermined amounts of other proteins such as lymphotoxin and/or interferon.

Glycosylated tumor necrosis factor also includes multimeric forms. TNF spontaneously aggregates into multimers, usually dimers or higher multimers. 15 Multimers are cytotoxic and accordingly are suitable for use in *vivo* therapy. While it is desirable to express and recover glycosylated TNF as a substantially homogeneous multimer or monomer, glycosylated TNF may be used therapeutically as a mixture of different multimers.

Derivatives of glycosylated TNF are included within the scope of the present invention. Derivatives include covalent or aggregative conjugates with other chemical moieties. Covalent derivatives are prepared by linkage of functionalities to groups which are found in the glycosylated TNF amino acid side chains or at the N- or C- terminal, by means known in the art. These derivatives may, for example, include aliphatic esters or amides of the carboxy terminus or residues containing carboxyl side chains; O-acyl derivatives of hydroxyl group-containing residues; and N-acyl derivatives of the amino terminal amino acid or amino-group containing residues, such as lysine or arginine. The acyl group is selected from the group of alkyl moieties, including C<sub>3</sub> to C<sub>10</sub> normal alkyl, thereby forming alkanoyl species, and carbocyclic or heterocyclic compounds, thereby forming aroyl species. The reactive groups

preferably are difunctional compounds known for use in cross-linking proteins to insoluble matrices through reactive side groups. Preferred derivatization sites are at cysteine and histidine residues.

Covalent or aggregative derivatives are useful as reagents in immunoassay or for affinity purification procedures. For example, glycosylated TNF is insolubilized by covalent bonding to cyanogen bromide-activated Sepharose by conventional methods or adsorbed to polyolefin surfaces, with or without glutaraldehyde cross-linking for use in the assay or purification of anti-TNF antibodies, cell surface receptors, or soluble extracellular portions thereof.

Glycosylated TNF may also be labeled with a detectable group, e.g., radioiodinated by the chloramine T procedure, covalently bound to rare earth chelates or conjugated to another fluorescent moiety for use in diagnostic assays, especially for diagnosis of glycosylated TNF levels in biological samples by competitive-type immunoassays. Such derivatives need not exhibit cytotoxic activity, only cross-reactivity with anti-TNF.

DNA which encodes glycosylated TNF can be obtained by chemical synthesis, by screening reverse transcripts of mRNA from peripheral blood lymphocytes or cell line cultures, or by screening genomic libraries from any cell. Glycosylated TNF is synthesized in host CHO (or other eukaryotic) cells transformed with vectors containing DNA encoding TNF. A vector is a replicable DNA construct. Vectors are used either to amplify DNA encoding TNF and/or to express DNA which encodes TNF. An expression vector is a replicable DNA construct in which a DNA sequence encoding TNF is operably linked to suitable control sequences capable of effecting the expression of TNF in CHO host cells. Such control sequences include a transcriptional promoter, an optional operator sequence to control transcription, a sequence encoding suitable mRNA ribosomal binding sites, and sequences which control termination of transcription and translation.

Vectors comprise plasmids, viruses (including phage), and integrable DNA fragments (i.e., integratable into the CHO genome by recombination). Once it

has transformed a CHO host, the vector replicates and functions independently of the host genome, or may, in some instances, integrate into the genome itself. In the present specification, "vector" is generic to "plasmid". However, all other forms of vectors which serve an equivalent function and which are, or become, known in the art are suitable for use herein. Suitable vectors contain replicon and control sequences which are derived from species compatible with the CHO host cells. Transformed host cells are CHO or other eukaryotic cells which have been transformed or transfected with tumor necrosis factor vectors constructed using recombinant DNA techniques. Transformed CHO or other eukaryotic host cells ordinarily express TNF.

10 DNA regions are operably linked when they are functionally related to each other. For example, DNA for a presequence or secretory leader is operably linked to DNA for a polypeptide if it is expressed as a preprotein which participates in the secretion of the polypeptide. A promoter is operably linked to a coding sequence if it controls the transcription of the sequence. A ribosome binding site is operably linked to a coding sequence if it is positioned so as to permit translation. Generally, but not necessarily, operably linked means contiguous, and, in the case of secretory leaders, contiguous and in reading phase.

15 Vectors must contain a promoter which is recognized by the host organism. This is generally a promoter homologous to the intended host.

20 Expression vectors for CHO cells ordinarily include, if necessary, an origin of replication, a promoter located upstream from the gene to be expressed, along with a ribosome binding site, RNA splice site (if intron-containing genomic DNA is used), a polyadenylation site, and a transcriptional termination sequence. The transcriptional and translational control sequences in expression vectors used in transforming CHO cells are often provided by viral sources. For example, commonly used promoters are derived from polyoma, Adenovirus 2, and Simian Virus 40 (SV40). The early and late promoters are particularly useful because both are obtained easily from the virus as a fragment which also contains the SV40 viral origin or replication. Smaller or larger SV40 fragments may also be used, provided the approximately 250

bp sequence extending from the Hind III site toward the Bg1 I site located in the viral origin of replication is included. Further, it is also possible, and often desirable, to use human genomic promoter, control, and/or signal sequences normally associated with TNF.

5 An origin of replication may be provided either by construction of the vector to include an exogenous origin, such as may be derived from SV40 or other viral (e.g., Polyoma, Adenovirus, VSV, or BPV source), or may be provided by the CHO cell replication mechanism. If the vector is integrated into the CHO host cell chromosome, the latter is often sufficient.

10 While CHO cells are disclosed as the preferred host cell it is expected that TNF- $\alpha$  recombinantly produced in any eukaryotic host cell system will be glycosylated in the same manner as the TNF- $\alpha$  obtained from CHO cells. Thus, for providing glycosylated human TNF- $\alpha$ , any suitable eukaryotic host cell system may be used.

15 Glycosylated TNF initially is recovered from cultures media. Transformed nonsecreting cells are lysed by sonication or other acceptable method and debris separated by centrifugation, while the supernatants from secreting cells (such as induced cell lines) are simply separated from the cells by centrifugation. Then, any one or more of the following steps may be used, or other methods entirely may be 20 substituted. The following method was used to purify glycosylated TNF to a degree sufficient for sequencing. This is not necessarily coextensive with the purification required for a therapeutic product.

25 As an initial purification step, glycosylated TNF is adsorbed onto a hydrophobic substance from the lysed culture of supernatant culture medium. The hydrophobic substance preferably is a nongelatinous hydrophobic surface such as a silicate or polyolefin, although alkyl Sepharose is also suitable. The preferred embodiment is controlled pore glass. A ratio of about one volume of controlled pore glass is mixed with 50 volumes of supernatant and the adsorption allowed to proceed at about 4°C without agitation over a period of about 30 minutes to two hours,

preferably about one hour, under slightly alkaline conditions. The adsorbent generally should thereafter be washed with a suitable buffer to remove entrapped contaminant proteins.

The adsorbed glycosylated TNF is eluted from the hydrophobic substance by altering the solvation properties of the surrounding medium. The elution can be accomplished by passing a solution buffered at approximately pH 7 to 8.5, preferably around 8, containing 1M salt and an effective amount of an aqueous solution of a water miscible organic polyol, such as, for example, ethylene glycol or glycerin, ordinarily ethylene glycol in the range of 10-30 percent v/v, preferably around 20 percent v/v. Of course, the optimum conditions will depend upon the polyol which is used. The glycosylated tumor necrosis factor-containing elution fractions are detected by any conventional assay.

Further purification may be obtained by adsorption of TNF onto a tertiary or quaternary amino anion exchange resin. The preferred resins for this purpose are hydrophilic matrix resins such as cross-linked polystyrene, dextran or cellulose substituted with alkyl tertiary or quaternary amino groups.

Purification to substantial homogeneity is achieved only upon further separation on SDS-PAGE electrophoresis or C4-reverse phase high pressure liquid chromatography.

This product, however, may not be desirable for therapeutic use, because it may lose substantial activity upon exposure to SDA or HPLC organic solvent.

Glycosylated tumor necrosis factor prepared according to the present invention is prepared for administration by mixing the glycosylated TNF having the desired degree of purity with physiologically acceptable carriers, i.e., carriers which are nontoxic to recipients at the dosages and concentrations employed. Ordinarily, this will entail combining the glycosylated TNF with buffers, antioxidants such as ascorbic acid, low molecular weight (less than about 10 residues) polypeptides, proteins, amino acids, carbohydrates including glucose or dextrans, chelating agents such as EDTA, and other stabilizers and excipients. The carrier should be formulated to stabilize the glycosylated TNF as a dimer and/or preferably, a trimer. This is accomplished by

6254561052-03070

avoiding salts or detergents in concentrations that dissociate tumor necrosis factor into monomers. Alternatively, conditions that aggregate glycosylated TNF into higher multimers should also be avoided. Generally a nonionic surfactant such as TWEEN 20 is employed to eliminate excessive aggregation during purification as well as 5 lyophilization or aqueous storage. Glycosylated TNF to be used for therapeutic administration must be sterile. This is readily accomplished by filtration through sterile filtration membranes. Glycosylated TNF ordinarily is stored in lyophilized form, or may simply be frozen.

Human TNF is known to be useful in the treatment of many human 10 diseases and conditions, either alone or with other active principles, such as interferon, or inactive carriers, diluents or excipients. The glycosylated human TNF of the present invention may be substituted for the non-glycosylated recombinantly-produced TNF in any of such applications and will provide increased half-life in body fluids, improved binding to receptors, and protection against the influence of proteases.

15 Examples of such indications include solid tumors, such as melanoma, EL-4 lymphoma, Meth-A tumors, melanocytes, carcinomas of the liver or lung, metastases or mammary carcinomas, and cancers including breast, anal, colorectal, head, neck and other body organs, leukemia, viral infections, cachexia, etc. Additionally, glycosylated human TNF can be used to prevent or mitigate parasitic, bacterial, and viral infections, 20 as well as prevention of autoimmune diseases. The glycosylated human TNF of the present invention may be formulated and administered as an injection, eye drop, nasal drop, inhalant, external preparation, oral preparation, rectal preparation, or vaginal preparation. The daily doses of the glycosylated recombinant human TNF may generally be in the range of from 50 to about 100,000,000 units. The daily dose may 25 be increased or decreased according to the direction for use and symptoms of the recipient.

The amount of glycosylated recombinant human tumor necrosis factor that is administered depends, for example, upon the route of administration, the condition in question, and the condition of the patient. Accordingly, it will be

necessary for the therapist to titer the dosage and modify the route of administration as required to obtain optimal activity for the patient. Such modification can be effected by one skilled in the art without undue experimentation.

The glycosylated human recombinant TNF prepared according to the present invention is particularly useful because, compared to non-glycosylated human TNF, the glycosylated TNF may have an increased half-life in body fluids, improved binding to receptors, and may be better protected against the influence of proteases. Accordingly, it should be understood that the glycosylated TNF- $\alpha$  of the present invention may be used for every indication in which prior art non-glycosylated TNF- $\alpha$  is currently known. Those of ordinary skill in this art will understand that the known protocols for formulation, administration and dosage for non-glycosylated TNF- $\alpha$  may be initially used for the glycosylated TNF- $\alpha$  of the present invention subject to experimental modification in light of the expected increased half-life and improved efficiency of the glycosylated form.

Glycosylated TNF can optionally be combined with other antineoplastic agents such as chemotherapeutic antibiotics such as actinomycin-D, adriamycin, aclacinomycin A, or with agents to augment or stimulate the immune response, such as immunoglobulins such as gamma globulin, including immunoglobulins having affinity for the cell surface antigens of neoplasms. In addition, since interferons act synergistically with TNF in cell lysis assay, alpha, beta or gamma interferon is desirably combined with glycosylated TNF composition or glycosylated TNF and lymphotoxin-containing composition. A typical formulation comprises glycosylated TNF and gamma interferon in a unit activity proportion of from about 0.1:1 to 200:1, ordinarily 10:1, and may contain lymphotoxin in place of a portion of the glycosylated TNF. These proportions, of course, are subject to modification as required by therapeutic experience.

Glycosylated TNF compositions may be administered to any tumor-bearing animals. The route of administration is in accord with known methods, e.g., intravenous, intraperitoneal, intramuscular, intralesional infusion or injection of

sterile glycosylated TNF solutions, or by timed release systems as noted below. Glycosylated TNF may be administered intralesionally, i.e., by direct injection into solid tumor. In the case of disseminated tumors such as leukemia, administration is preferably intravenous or into the lymphatic system. Tumors of the abdominal organs such as ovarian cancer are advantageously treated by intraperitoneal infusion using peritoneal dialysis hardware and peritoneal-compatible solutions. Ordinarily, however, glycosylated TNF is administered continuously by infusion, although bolus injection is acceptable.

Glycosylated TNF can also be administered from an implantable timed-release article. Examples of suitable systems for proteins having the molecular weight of glycosylated TNF dimers or trimers include copolymers of L-glutamic acid and gamma ethyl-L-glutamate, poly(2-hydroethyl-methacrylate) or ethylene vinyl acetate. Such an article is implanted at surgical sites from which tumors have been excised. Alternatively, glycosylated TNF is encapsulated in semipermeable microcapsules or liposomes for injection into the tumor. This mode of administration is particularly useful for surgically inexcisable tumors such as brain tumors. The amount of glycosylated TNF that is administered will depend, for example, upon the route of administration, the tumor in question and the condition of the patient. Intralesional injections will require less glycosylated TNF on a body weight basis than will intravenous infusion, while some tumor types, e.g., solid tumors, appear to be more resistant to glycosylated TNF than other, e.g., leukemic. Accordingly, it is necessary for the therapist to titer the dosage and modify the route of administration as required to obtain the optimal cytotoxic activity towards the target tumor, as can be determined, for example, by biopsy of the tumor or diagnostic assays for putative cancer markers such as carcinoembryonic antigen, in view of any recombinant toxicity encountered at elevated dosage.

**Example 1: Production of Recombinant Human TNF from Chinese Hamster Ovary Cells**

A clone expressing recombinant human TNF made in the manner described in Korn et al, *supra*, the entire contents of which are hereby incorporated by reference, was obtained from the laboratory of Prof. D. Wallach, Weizmann Institute of Science, Rehovot, Israel. The clone was propagated in Dulbecco Modified Eagle's Medium (DMEM) supplemented with proline, glutamine and 10% fetal bovine serum until production started. Production was carried out in a one-liter spinner with disc carriers. The spinner was seeded with  $2.5 \times 10^9$  cells, which were maintained in serum-supplemented medium for five days, after which the medium was changed to production medium (DMEM, ADC-1 supplement, Beit Haemek Industries, Israel), 0.2  $\mu$ g per ml insulin and 0.5  $\mu$ g protein per ml serum active fraction. Production was carried out in serum-free medium. Two harvests were collected every day and the spinner was kept running in production for three months. Crude concentrated recombinant human TNF was purified on an affinity column which contained recombinant human tumor necrosis binding protein coupled to Fractogel TSK-AF-CDI resin, a resin manufactured by Toso-Haas.

More specifically, the glycosylated human TNF is purified using the following steps:

- 20 1. Clarification and concentration
2. Affinity chromatography column
3. Concentration, dialysis to the final buffer and terminal filtration

**Filtration and Concentration**

25 Recombinant human TNF crude harvest was clarified on a 1.2 micron filter and then concentrated 20-fold in the Pellicon system with 10 kDa cut-off membrane. The concentrated crude harvest was maintained at -70°C until use. Before being loaded onto the column, the thawed crude was filtered through 0.2 micron filter

in order to remove microorganisms and particles which were created as a result of the freezing/thawing action.

In general, it is not recommended to concentrate crude glycosylated TNF more than 20-fold, since further concentration of the 2% serum proteins might damage the biologically active protein in the crude. However, this limitation is irrelevant for the present invention, since the TNF is produced in low protein content serum-free medium.

#### Affinity Chromatography Column

Crude concentrated recombinant human TNF was purified on an affinity column which contains recombinant human TNF Binding Protein-1 (TBP-1), the TNF receptor, soluble p55 coupled to 56 ml of Fractogel TSK-AF-CDI resin (Merck). The recombinant human TNF binding protein was chosen for this purpose based upon the high association constant of TNF to its soluble receptor, TBP-1. The coupling procedure involved overnight shaking of 4.5 mg/ml concentrated recombinant human TBP-1 in 0.1 M phosphate buffer (pH 7.5) with the resin. The binding ratio is 7-8 mg recombinant human TBP-1 per ml resin. Note that one gram of resin is self-rising to 3.5 ml when suspended with the reaction liquid.

#### TBP-CDI Column

The chromatography procedure consisted of loading the crude onto the column which had been pre-equilibrated with PBS, washing the 30 bed volumes of HSPB and washing back to PBS (30 bed volumes) before the start of the elution. The elution was carried out with 100 mM NaCl in 50 mM citric acid (pH 2.5). The elution main peak was cut at 65% of its way down and collected into 2 M Tris (pH 8.5) for titration of the acidic pH (which is destructive to TNF activity) to pH 8. The titration was performed in a ratio of 400 microliters Tris per 5 ml of elution buffer. After the elution peak returned to baseline, the column was regenerated with 10 bed volumes of

50 mM citric acid without NaCl and then regenerated with 20 bed volumes of HSPB. The following flow chart lists all of the column's run steps:

**TBP 1-CDI COLUMN AFFINITY CHROMATOGRAPHY**

DO NOT USE FOR REPRODUCTION

5

Equilibration with PBS



Load and wash with PBS



10 Wash with HSPB



Wash with PBS



15 Elution with 0.1 M NaCl in 50 nM Citric Acid (pH2.5)

into unbuffered Tris base



Column regeneration with 50 mM Citric Acid



20 Regeneration with HSPB

20

*Note: In this production campaign, the PBS wash before elution was omitted.*

25

At the end of the chromatography cycle, the column was washed with 20 bed volumes of 1 M NaCl and 0.05% NaN<sub>3</sub> and maintained in this buffer at 4°C.

Table 1 shows a typical distribution of the recombinant human TNF through the column fractions as measured by spectrophotometric measurement (A<sub>280</sub>/EC) and bioassay.

TABLE 1

FRACTION	VOLUME (ml)	A <sub>280</sub>	A <sub>280</sub> /EC (mg/ml)	A <sub>280</sub> /EC TOTAL (mg)	BIO ASSAY (MU/ml)	BIO ASSAY (mg/ml)	BIO ASSAY TOTAL (mg)
Input	900	N.D.	-	-	1.47x10 <sup>6</sup>	0.0036	33
El-2	138	0.213	0.173	23.8	5.59x10 <sup>6</sup>	0.127	18.9

5      Concentration and Dialysis

10      The elution fractions from several chromatography cycles were pooled together and concentrated in a Filtron Minisette system with 10kDa cutoff membrane to a concentration of 1.65 mg/ml according to absorbance (A<sub>280</sub> divided by the extinction coefficient, A<sub>280</sub>/EC). The concentrated pool was dialyzed against 20mM Tris-CH<sub>3</sub>; 100mM NaCl (pH 8.0).

Material Distribution Throughout the Columns

A summary of the material balance results is presented in the tables below.

Table 2 shows a typical yield of the CDI-TBP-1 affinity column.

**TABLE 2**

TEST PARAMETER	METHOD/ (A <sub>280</sub> /EC)/BIOASSAY	BIOASSAY
RECOVERY (%)	72.9	57.3

Table 3 shows a typical distribution for the r-hTNF through the column's fractions in the reprocess chromatography, as measured by A280/EC and Bioassay.

TABLE 3

FRACTION	VOLUME (ml)	A <sub>280</sub>	A <sub>280</sub> /EC (mg/ml)	A <sub>280</sub> /EC TOTAL	BIO ASSAY (MU/ml)	BIO ASSAY (mg/ml)	BIO ASSAY TOTAL (mg)
Input	130	0.191	0.156	20.28	4.88	0.119	15.47
U.B.	200	U.L.			N.D.		
HSPB-1	215	U.L.			N.D.		
EL-1	80	U.L.			N.D.		
EL-2	120	0.146	0.119	14.28	3.82	0.094	11.28
EL-3	130	U.L.			N.D.		
EL pH 2.5	135	0.003	0.002	0.27	N.D.		
50 mM citric	50	0.005	0.004	0.20	N.D.		
HSPB II	125	0.048	0.039	4.87	N.D.		

\* N.D. = Not Done

5    \*\* U.L. = Under LOD = Under limit of detection

Table 4 shows a typical yield and column balance summary.

TABLE 4

TEST METHOD/ PARAMETER	(A <sub>280</sub> /EC)/ BIOASSAY	BIOASSAY
RECOVERY (%)	70.4	72.9
BALANCE	96.7	N.D.

\* N.D. = Not done

5 Pure recombinant human TNF was tested by six analytical techniques: carbohydrate composition, carbohydrate mapping, gel electrophoresis (SDS-PAGE), isoelectric focusing, capillary electrophoresis, and reverse phase high performance liquid chromatography.

Monosaccharide composition

10 Aliquots of recombinant human TNF prepared as above were hydrolyzed using three different sets of conditions:

- (1) Release of amino sugars with 4M HCl;
- (2) Release of neutral sugars with 2M trifluoroacetic acid;
- (3) Release of sialic acid with 0.1M HCl.

15 The released monosaccharides were separated on the Dionex system. The system is comprised of a pump, pulsed electrochemical detector, autosampler, and an anion exchange column. An isocratic elution using 16 mM NaOH was used for the separation, identification and quantitation of the neutral and amino monosaccharides.

Sialic acid was separated on the same anion exchange column with a gradient of

20 30-990 mM sodium acetate in 100 mM NaOH.

Oligosaccharide Mapping

Chemical release of oligosaccharide was performed on a GlycoPrep-1000 system from Oxford GlycoSystems. The GP-1000 is a bench-top chemical reactor which automatically cleaves the glycosidic bond with anhydrous hydrazine. The GP-1000 can operate in three modes: N, N+O and O. These modes give a preferential release of N-linked, O-linked or both, through lower recoverY (about 85%).

Two aliquots were hydrazinolysed by the GP-1000, one in the O-mode (Fig. 1A) and a second in the N+O mode (Fig. 1B). The released oligosaccharides were separated and identified by the Dionex system with a PA-100 column.

## Gel Electrophoresis (SDS-PAGE)

A 20% acrylamide SDS gel using a tall Mighty Small apparatus (Hoeffer) was used to separate and compare recombinant human TNF samples from Chinese hamster ovary cells, as well as from *E. coli*, and aliquots of TNF incubated with enzymes. The gel was loaded with 3 micrograms protein of each sample and stained for 30 minutes with Coomassie R-250.

## Isoelectric Focusing

The separation of charged glycoforms was effected using 0.25 mm thick  
20 gel in a 13 x 26 cm. casting unit. The gel composition was 2.6% acrylamide, 4%  
ampholytes, and 10% glycerol. Five micrograms of each sample were loaded. The gel  
was run for 5000 Volt-hours, using 0.2 M NaOH as cathode solution and 0.2 M  
H<sub>3</sub>PO<sub>4</sub> as anode solution.

## 25 Capillary Electrophoresis

TNF samples were separated by capillary zone electrophoresis on an ABI Capillary Electrophoresis system (270A-HT, Applied Biosystems). The electrophoresis conditions were as follows:

Buffer: 100 mM phosphate (pH 2.5)

Capillary: 72 mm length capillary

Detection: 200 nm

Voltage: 20 kV

5 Reverse Phase High Performance Liquid Chromatography

The chromatographic conditions used in this test were based on those described in European Patent 168214. The chromatography was conducted at room temperature using a C4 RP-HPLC column, 25cm x 4.6 mm, and eluted with a gradient of 1-propanol in 0.1% trifluoroacetic acid. Detection was at 280 nm on a UV detector.

10

Results

Carbohydrate Composition

The results from the monosaccharide composition assayed on the Doinex system indicated that galactose amine, galactose, and sialic acid were present in the TNF molecule produced according to the present invention. The ratio of 1:1:1.5 was obtained and reconfirmed. This ratio and composition indicates an O-linked oligosaccharide.

15

Carbohydrate Mapping

20

In order to demonstrate that the recombinant TNF produced from Chinese hamster ovary cells is a glycoprotein with O-linked oligosaccharide, a chemical release of the

25

oligosaccharide was performed using the GlycoPrep-1000. The released oligoforms were separated by high performance anion exchange pulsed electrochemical detector on the Dionex system. The oligomap results obtained are shown in Figures 1A and 1B. In the GlycoPrep-1000 "O-mode" (Fig. 1A), only one peak of oligosaccharide was detected, eluting in the chromatogram at the same time as O-linked oligosaccharide standards run separately (data not shown). The released oligosaccharide in the "N+O" mode (Fig. 1B) gave the same chromatogram with no additional peaks, indicating the

0  
1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65  
66  
67  
68  
69  
70  
71  
72  
73  
74  
75  
76  
77  
78  
79  
80  
81  
82  
83  
84  
85  
86  
87  
88  
89  
90  
91  
92  
93  
94  
95  
96  
97  
98  
99  
100  
101  
102  
103  
104  
105  
106  
107  
108  
109  
110  
111  
112  
113  
114  
115  
116  
117  
118  
119  
120  
121  
122  
123  
124  
125  
126  
127  
128  
129  
130  
131  
132  
133  
134  
135  
136  
137  
138  
139  
140  
141  
142  
143  
144  
145  
146  
147  
148  
149  
150  
151  
152  
153  
154  
155  
156  
157  
158  
159  
160  
161  
162  
163  
164  
165  
166  
167  
168  
169  
170  
171  
172  
173  
174  
175  
176  
177  
178  
179  
180  
181  
182  
183  
184  
185  
186  
187  
188  
189  
190  
191  
192  
193  
194  
195  
196  
197  
198  
199  
200  
201  
202  
203  
204  
205  
206  
207  
208  
209  
210  
211  
212  
213  
214  
215  
216  
217  
218  
219  
220  
221  
222  
223  
224  
225  
226  
227  
228  
229  
2210  
2211  
2212  
2213  
2214  
2215  
2216  
2217  
2218  
2219  
2220  
2221  
2222  
2223  
2224  
2225  
2226  
2227  
2228  
2229  
2230  
2231  
2232  
2233  
2234  
2235  
2236  
2237  
2238  
2239  
2240  
2241  
2242  
2243  
2244  
2245  
2246  
2247  
2248  
2249  
2250  
2251  
2252  
2253  
2254  
2255  
2256  
2257  
2258  
2259  
22510  
22511  
22512  
22513  
22514  
22515  
22516  
22517  
22518  
22519  
22520  
22521  
22522  
22523  
22524  
22525  
22526  
22527  
22528  
22529  
22530  
22531  
22532  
22533  
22534  
22535  
22536  
22537  
22538  
22539  
22540  
22541  
22542  
22543  
22544  
22545  
22546  
22547  
22548  
22549  
22550  
22551  
22552  
22553  
22554  
22555  
22556  
22557  
22558  
22559  
22560  
22561  
22562  
22563  
22564  
22565  
22566  
22567  
22568  
22569  
22570  
22571  
22572  
22573  
22574  
22575  
22576  
22577  
22578  
22579  
22580  
22581  
22582  
22583  
22584  
22585  
22586  
22587  
22588  
22589  
22590  
22591  
22592  
22593  
22594  
22595  
22596  
22597  
22598  
22599  
225100  
225101  
225102  
225103  
225104  
225105  
225106  
225107  
225108  
225109  
225110  
225111  
225112  
225113  
225114  
225115  
225116  
225117  
225118  
225119  
225120  
225121  
225122  
225123  
225124  
225125  
225126  
225127  
225128  
225129  
225130  
225131  
225132  
225133  
225134  
225135  
225136  
225137  
225138  
225139  
225140  
225141  
225142  
225143  
225144  
225145  
225146  
225147  
225148  
225149  
225150  
225151  
225152  
225153  
225154  
225155  
225156  
225157  
225158  
225159  
225160  
225161  
225162  
225163  
225164  
225165  
225166  
225167  
225168  
225169  
225170  
225171  
225172  
225173  
225174  
225175  
225176  
225177  
225178  
225179  
225180  
225181  
225182  
225183  
225184  
225185  
225186  
225187  
225188  
225189  
225190  
225191  
225192  
225193  
225194  
225195  
225196  
225197  
225198  
225199  
225200  
225201  
225202  
225203  
225204  
225205  
225206  
225207  
225208  
225209  
225210  
225211  
225212  
225213  
225214  
225215  
225216  
225217  
225218  
225219  
225220  
225221  
225222  
225223  
225224  
225225  
225226  
225227  
225228  
225229  
225230  
225231  
225232  
225233  
225234  
225235  
225236  
225237  
225238  
225239  
225240  
225241  
225242  
225243  
225244  
225245  
225246  
225247  
225248  
225249  
225250  
225251  
225252  
225253  
225254  
225255  
225256  
225257  
225258  
225259  
225260  
225261  
225262  
225263  
225264  
225265  
225266  
225267  
225268  
225269  
225270  
225271  
225272  
225273  
225274  
225275  
225276  
225277  
225278  
225279  
225280  
225281  
225282  
225283  
225284  
225285  
225286  
225287  
225288  
225289  
225290  
225291  
225292  
225293  
225294  
225295  
225296  
225297  
225298  
225299  
225300  
225301  
225302  
225303  
225304  
225305  
225306  
225307  
225308  
225309  
225310  
225311  
225312  
225313  
225314  
225315  
225316  
225317  
225318  
225319  
225320  
225321  
225322  
225323  
225324  
225325  
225326  
225327  
225328  
225329  
225330  
225331  
225332  
225333  
225334  
225335  
225336  
225337  
225338  
225339  
225340  
225341  
225342  
225343  
225344  
225345  
225346  
225347  
225348  
225349  
225350  
225351  
225352  
225353  
225354  
225355  
225356  
225357  
225358  
225359  
225360  
225361  
225362  
225363  
225364  
225365  
225366  
225367  
225368  
225369  
225370  
225371  
225372  
225373  
225374  
225375  
225376  
225377  
225378  
225379  
225380  
225381  
225382  
225383  
225384  
225385  
225386  
225387  
225388  
225389  
225390  
225391  
225392  
225393  
225394  
225395  
225396  
225397  
225398  
225399  
225400  
225401  
225402  
225403  
225404  
225405  
225406  
225407  
225408  
225409  
225410  
225411  
225412  
225413  
225414  
225415  
225416  
225417  
225418  
225419  
225420  
225421  
225422  
225423  
225424  
225425  
225426  
225427  
225428  
225429  
225430  
225431  
225432  
225433  
225434  
225435  
225436  
225437  
225438  
225439  
225440  
225441  
225442  
225443  
225444  
225445  
225446  
225447  
225448  
225449  
225450  
225451  
225452  
225453  
225454  
225455  
225456  
225457  
225458  
225459  
225460  
225461  
225462  
225463  
225464  
225465  
225466  
225467  
225468  
225469  
225470  
225471  
225472  
225473  
225474  
225475  
225476  
225477  
225478  
225479  
225480  
225481  
225482  
225483  
225484  
225485  
225486  
225487  
225488  
225489  
225490  
225491  
225492  
225493  
225494  
225495  
225496  
225497  
225498  
225499  
225500  
225501  
225502  
225503  
225504  
225505  
225506  
225507  
225508  
225509  
225510  
225511  
225512  
225513  
225514  
225515  
225516  
225517  
225518  
225519  
225520  
225521  
225522  
225523  
225524  
225525  
225526  
225527  
225528  
225529  
225530  
225531  
225532  
225533  
225534  
225535  
225536  
225537  
225538  
225539  
225540  
225541  
225542  
225543  
225544  
225545  
225546  
225547  
225548  
225549  
225550  
225551  
225552  
225553  
225554  
225555  
225556  
225557  
225558  
225559  
225560  
225561  
225562  
225563  
225564  
225565  
225566  
225567  
225568  
225569  
225570  
225571  
225572  
225573  
225574  
225575  
225576  
225577  
225578  
225579  
225580  
225581  
225582  
225583  
225584  
225585  
225586  
225587  
225588  
225589  
225590  
225591  
225592  
225593  
225594  
225595  
225596  
225597  
225598  
225599  
2255100  
2255101  
2255102  
2255103  
2255104  
2255105  
2255106  
2255107  
2255108  
2255109  
2255110  
2255111  
2255112  
2255113  
2255114  
2255115  
2255116  
2255117  
2255118  
2255119  
2255120  
2255121  
2255122  
2255123  
2255124  
2255125  
2255126  
2255127  
2255128  
2255129  
2255130  
2255131  
2255132  
2255133  
2255134  
2255135  
2255136  
2255137  
2255138  
2255139  
2255140  
2255141  
2255142  
2255143  
2255144  
2255145  
2255146  
2255147  
2255148  
2255149  
2255150  
2255151  
2255152  
2255153  
2255154  
2255155  
2255156  
2255157  
2255158  
2255159  
2255160  
2255161  
2255162  
2255163  
2255164  
2255165  
2255166  
2255167  
2255168  
2255169  
2255170  
2255171  
2255172  
2255173  
2255174  
2255175  
2255176  
2255177  
2255178  
2255179  
2255180  
2255181  
2255182  
2255183  
2255184  
2255185  
2255186  
2255187  
2255188  
2255189  
2255190  
2255191  
2255192  
2255193  
2255194  
2255195  
2255196  
2255197  
2255198  
2255199  
2255200  
2255201  
2255202  
2255203  
2255204  
2255205  
2255206  
2255207  
2255208  
2255209  
2255210  
2255211  
2255212  
2255213  
2255214  
2255215  
2255216  
2255217  
2255218  
2255219  
2255220  
2255221  
2255222  
2255223  
2255224  
2255225  
2255226  
2255227  
2255228  
2255229  
2255230  
2255231  
2255232  
2255233  
2255234  
2255235  
2255236  
2255237  
2255238  
2255239  
2255240  
2255241  
2255242  
2255243  
2255244  
2255245  
2255246  
2255247  
2255248  
2255249  
2255250  
2255251  
2255252  
2255253  
2255254  
2255255  
2255256  
2255257  
2255258  
2255259  
2255260  
2255261  
2255262  
2255263  
2255264  
2255265  
2255266  
2255267  
2255268  
2255269  
2255270  
2255271  
2255272  
2255273  
2255274  
2255275  
2255276  
2255277  
2255278  
2255279  
2255280  
2255281  
2255282  
2255283  
2255284  
2255285  
2255286  
2255287  
2255288  
2255289  
2255290  
2255291  
2255292  
2255293  
2255294  
2255295  
2255296  
2255297  
2255298  
2255299  
2255300  
2255301  
2255302  
2255303  
2255304  
2255305  
2255306  
2255307  
2255308  
2255309  
2255310  
2255311  
2255312  
2255313  
2255314  
2255315  
2255316  
2255317  
2255318  
2255319  
2255320  
2255321  
2255322  
2255323  
2255324  
2255325  
2255326  
2255327  
2255328  
2255329  
2255330  
2255331  
2255332  
2255333  
2255334  
2255335  
2255336  
2255337  
2255338  
2255339  
2255340  
2255341  
2255342  
2255343  
2255344  
2255345  
2255346  
2255347  
2255348  
2255349  
2255350  
2255351  
2255352  
2255353  
2255354  
2255355  
2255356  
2255357  
2255358  
2255359  
2255360  
2255361  
2255362  
2255363  
2255364  
2255365  
2255366  
2255367  
2255368  
2255369  
2255370  
2255371  
2255372  
2255373  
2255374  
2255375  
2255376  
2255377  
2255378  
2255379  
2255380  
2255381  
2255382  
2255383  
2255384  
2255385  
2255386  
2255387  
2255388  
2255389  
2255390  
2255391  
2255392  
2255393  
2255394  
2255395  
2255396  
2255397  
2255398  
2255399  
2255400  
2255401  
2255402  
2255403  
2255404  
2255405  
2255406  
2255407  
2255408  
2255409  
2255410  
2255411  
2255412  
2255413  
2255414  
2255415  
2255416  
2255417  
2255418  
2255419  
2255420  
2255421  
2255422  
2255423  
2255424  
2255425  
2255426  
2255427  
2255428  
2255429  
2255430  
2255431  
2255432  
2255433  
2255434  
2255435  
2255436  
2255437  
2255438  
2255439  
2255440  
2255441  
2255442  
2255443  
2255444  
2255445  
2255446  
2255447  
2255448  
2255449  
2255450  
2255451  
2255452  
2255453  
2255454  
2255455  
2255456  
2255457  
2255458  
2255459  
2255460  
2255461  
2255462  
2255463  
2255464  
2255465  
2255466  
2255467  
2255468  
2255469  
2255470  
2255471  
2255472  
2255473  
2255474  
2255475  
2255476  
2255477  
2255478  
2255479  
2255480  
2255481  
2255482  
2255483  
2255484  
2255485  
2255486  
2255487  
2255488  
2255489  
2255490  
2255491  
2255492  
2255493  
2255494  
2255495  
2255496  
2255497  
2255498  
2255499  
2255500  
2255501  
2255502  
2255503  
2255504  
2255505  
2255506  
2255507  
2255508  
2255509  
2255510  
2255511  
2255512  
2255513  
2255514  
2255515  
2255516  
2255517  
2255518  
2255519  
2255520  
2255521  
2255522  
2255523  
2255524  
2255525  
2255526  
2255527  
2255528  
2255529  
2255530  
2255531  
2255532  
2255533  
2255534  
2255535  
2255536  
2255537  
2255538  
2255539  
2255540  
2255541  
2255542  
2255543  
2255544  
2255545  
2255546  
2255547  
2255548  
2255549  
2255550  
2255551  
2255552  
2255553  
2255554  
2255555  
2255556  
2255557  
2255558  
2255559  
2255560  
2255561  
2255562  
2255563  
2255564  
2255565  
2255566  
2255567  
2255568  
2255569  
2255570  
2255571  
2255572  
2255573  
2255574  
2255575  
2255576  
2255577  
2255578  
2255579  
2255580  
2255581  
2255582  
2255583  
2255584  
2255585  
2255586  
2255587  
2255588  
2255589  
2255590  
2255591  
2255592  
225

absence of any known N-linked oligosaccharide. Other oligosaccharides may be present in minor amounts.

#### Gel Electrophoresis

5 TNF prepared according to the present invention was incubated with neuraminidase for two hours to remove sialic acid. An aliquot was further incubated with O-glycanase for 18 hours. From that sample, an aliquot was further incubated with N-glycanase for 18 hours. Samples were kept frozen at -70°C until analysis.

10 The gel obtained, (not shown) showed a major band at 17,000 Daltons, primarily TNF, and an additional band with a higher molecular weight, presumably a glycosylated form of recombinant human TNF. When incubated with neuraminidase, most of the glycosylated form turned into the 17,000 Daltons band. The gel indicated the presence of enzyme-sensitive glycoforms, affecting mainly the sialic acid and the 15 O-linked glycans.

#### Isoelectric Focusing

20 Isoelectric focusing gels performed with recombinant TNF produced from Chinese hamster ovary cells and recombinant TNF produced from *E. coli* indicated that the major bands are similar (not shown). Extra bands observed with TNF produced in CHO cells were sensitive to enzymatic digestion.

25 Incubation with neuraminidase removed most of the extra bands at pI=5.85 and 5.2. The removal of the acidic charged group, sialic acid, resulted in increase in the level of the basic forms. The other enzymatic incubations did not further affect charge and, thus, did not alter migration in the isoelectric focusing analysis.

#### Capillary Electrophoresis

Figure 2 represents the electropherograms obtained in capillary electrophoresis assays. Figure 2A shows the results of capillary electrophoresis of recombinant human TNF from CHO cells; 2B shows the results for recombinant human TNF from CHO cells + neuraminidase; 2C shows results from recombinant human TNF from CHO cells plus neuraminidase plus O-glycanase; 2D shows the results for recombinant human TNF from CHO cells plus neuraminidase plus O-glycanase plus N-glycanase; and 2E shows the results of capillary electrophoresis analysis of recombinant human TNF produced in *E. coli*.

The profile of TNF produced by CHO cells, Figure 2A, exhibits a main peak, which is probably unglycosylated recombinant human TNF, as well as additional peaks not present in the *E. coli* recombinant human TNF, Figure 2E. The glycosylated peaks represent about 35% of the molecules.

Figure 2B demonstrates that neuraminidase removed most of the charge, sialic acid, and that O-glycanase removed the oligosaccharide core, as shown in Figure 2C. Figure 2D shows that additional incubation with N-glycanase did not alter the electropherogram.

#### Reverse Phase High Performance Liquid Chromatography

When recombinant human TNF prepared in CHO cells and recombinant human TNF prepared in *E. coli* were subjected to reverse phase high performance liquid chromatography, the two compounds co-eluted, indicating a resemblance in the protein core. Chromatograms of recombinant human TNF from CHO and *E. coli* showed the two proteins as co-migrating proteins.

#### Summary of Characterization Tests

The above assays clearly demonstrated that recombinant human TNF prepared in CHO cells has an additional form not present on recombinant human TNF obtained from *E. coli*. The form from CHO cells was found to be O-glycosylated. All of the tests performed indicated that recombinant human TNF obtained from CHO

cells is similar to recombinant human TNF from *E. coli* in the protein core, but differs in that the CHO TNF is glycosylated. The nature of the glycosylated form was determined by composition analysis, oligomap and capillary electrophoresis.

## 5 Purity Determination of TNF Bulk by SDS-PAGE Analyses

A limit testm whereby various amounts of the final TNF bulk were run on SDS-PAGE and stained by Coomassie blue. The limit of detection of HSA on the gel is 150 ng and the maximum load of TNF was 40 micrograms per lane. There was no visible impurity band in the TNF lanes. The conclusion therefore is that there is no single contaminant band which is higher than 0.37%.

In conducting these assays, samples applied on the gel were: (1) Sample buffer; (2) 10 micrograms TNF Bulk-2; (3) 20 micrograms TNF-Bulk 2; (4) 40 micrograms TNF Bulk-2; (5) 75 ng HSA; (6) 100 ng HSA; (7) 150 ng HSA; (8) LMW markers

Qualitative purity were obtained by SDS-PAGE-silver stained. In obtaining the results, 9 and 18 micrograms of the final TNF Bulk were run on SDS-PAGE and stained by silver stain. The samples applied on the gel were: (1) Sample buffer; (2) 9 micrograms TNF Bulk-1; (3) 9 micrograms TNF Bulk-2; (4) 18 micrograms TNF Bulk-2; (5) LMW markers. No impurity was visible.

### TNF-Bulk Concentration

The final bulk concentration was determined by a variety of analytical test methods: Bradford, A280/E.C., ELISA and bioassay. The results are summarized in Table 5.

28  
TABLE 5

TEST METHOD	RESULT
BRADFORD	1265 $\mu$ g/ml
ELISA	1658 $\mu$ g/ml
$A_{280}$ /E.C.	1651 $\mu$ g/ml
BIOASSAY	50.87 MU/ml

5 Size Exclusion Chromatography

Size exclusion chromatography was performed. Its purpose was to determine the purity and the molecular weight of the TNF form which is present in the final bulk. The SEC profile revealed one major peak with apparent MW by retention time of about 50 kD. It is known from the literature, and from our SDS-PAGE analysis, that the TNF molecular weight is 17 kD. The conclusion is that TNF exists in the bulk in the trimer form which is reported to be the bioactive form.

10 Isoelectric Focusing

Isoelectric focusing was performed. The final bulk has seven isoelectric forms in the pH range of 5-7. When r-hTNF Bulk-1 was treated with neuraminidase, it collapsed to one isoelectric form. The conclusion is that all the other forms are probably glycosylated.

15 Isoelectric focusing of r-hTNF Bulk samples was conducted on gel -5% total acrylamide 2.6% bis-acrylamide containing 2% ampholytes, 32% (v/v) glycerol, 20 10 mM GLU, 10 mM LYS, pH gradients 3-10, 15 cm wide (anode to cathode), run conditions: 15°C, 20,000 V/hr.

Samples applied on the gel were: (1) Internal marker (cytochrome C); (2) pH markers; (3) 5 microliters 0.5 mg/ml TNF Bulk-1; (4) 5 microliters 0.5 mg/ml TNF Bulk-1; (5) 5 microliters 0.5 mg/ml TNF Bulk-2; (6) 0.5 mg/ml TNF Bulk-2; (7) 0.5 microliters 1.65 mg/ml TNF Bulk-2; (8) 5 microliters 1.65 mg/ml TNF Bulk-2; (9) pH markers.

The final bulk was checked for its amino acid composition and the results are shown in Table 6:

0545005000000000

30  
**TABLE 6**

*Amino Acid Composition*

Sample TNF - Bulk 2

Aminolab No. A01590894.9H-HP

5 Molec. Wt. 16606.28

Smplwt. mg 0.087

Vol sampled, ul 60

S.B. Vol ul 330

InjVol ul 50

10 Analysis Date 19.8.94 Diln. 7.5825E-03

Hydrolyzed by Gas Phase

	<u>No.</u>	<u>ACID</u>	<u>residues</u>	<u>50</u>	<u>% in sample</u>	<u>Amt/run, nM</u>
15	2	ASX	12.25		8.490	9.73
	4	THR	6.13		3.733	4.87
	5	SER	35	12.28	6.437	9.75
	6	GLX		11.12	8.644	8.83
	7	PRO		10.38	6.067	8.24
20	8	GLY		11.47	3.941	9.11
	9	ALA		13.96	5.976	11.09
	10	1/2 CYS	40	2.19	1.361	1.74
	11	VAL		15.02	8.967	11.93
	13	ILE		8.85	6.031	7.03
25	14	LEU		18.19	12.397	14.45
	15	TYR		7.35	7.225	5.84
	16	PHE	45	4.18	3.705	3.32
	17	HIS		3.34	2.756	2.65
	18	LYS		6.47	4.995	5.14
30	<u>20</u>	<u>ARG</u>	<u>9.86</u>		<u>9.273</u>	<u>7.83</u> 121.55
		Total-	153.05		100.00	

N-Terminal Amino Acid Sequence

The final bulk was checked for N-terminal amino acid sequence, and the results showed a sequence known from the literature:

Val-Arg-Ser-Ser-Ser-Arg-Thr-Pro-Ser-Asp-Lys-Pro-Val-Ala-His (SEQ ID NO:1)

5

Endotoxins Concentration

The final bulk was checked for endotoxin concentration by the LAL test, and the results showed endotoxin concentration of less than 0.25 EU/ml, or less than 0.15 EY/mg.

10

The tests results for Recombinant TNF Bulk are shown in Table 7:

09445102-030700

**TABLE 7**  
**TNF-RECOMBINANT BULK**

5 Product: CHO r-TNF-1 Issue Date: 4.10.94  
 Bulk No.: TNF-Bulk-2 Production Date: 8.8.94

General Description	
PH	8.0
CONDUCTIVITY	12.6 mS/cm
A <sub>280</sub>	2.025 A <sub>280</sub> /ml
PROTEIN CONCENTRATION (A <sub>280</sub> /E.C.) <sup>*</sup>	1.65 mg/ml
PROTEIN CONCENTRATION (Bradford)	1.265 mg/ml
Identity	
MOLECULAR WEIGHT (SEC)	49.89 KD
ISOELECTRIC FOCUSING (IEF)	CONFORMS with TNF Bulk-1
N-TERMINAL SEQUENCING	CONFORMS**
AMINO ACID ANALYSIS(A.A.A.)	CONFORMS with TNF Bulk-1
Potency	
BIOASSAY***	50.87 U/ml
ELISA***	1.65 mg/ml
Purities & Impurities	
% PURITIES BY SDS-PAGE	99.5%
PURITY PROFILE BY SDS-PAGE	CONFORMS with TNF Bulk-1
TBP LEVEL	LT 0.01 ng/µg
Safety	
ENDOTOXINS BY LAL	LT 0.15 EU/mg

10 \* Extinction Coefficient = 1.226 (A<sub>280</sub> per mg/ml)

\*\* Identity to the sequence known from the literature

\*\*\* NBSB Standard

Within the scope of the present invention are fragments of glycosylated TNF or mutants of glycosylated TNF or its fragments (including mature TNF) wherein one or more amino acid residues are substituted, inserted or deleted as long as such fragments or mutants retain the biological activity of the r-hTNF- $\alpha$ .

5        The degree of amino acid sequence homology which brings a polypeptide within the scope of the definition of glycosylated tumor necrosis factor fragments or mutants herein will vary depending upon whether the homology between the candidate protein and glycosylated tumor necrosis factor falls within or without the tumor necrosis factor regions responsible for cytotoxic activity. Domains which are 10      critical for cytotoxic activity should exhibit a high degree of homology in order to fall within the definition, while sequences not involved in maintaining glycosylated TNF conformation or in effecting receptor binding may show comparatively low homology. In addition, critical domains may exhibit cytolytic activity and yet remain homologous 15      as defined herein if residues containing functionally similar amino acid side chains are substituted. Functionally similar refers to dominant characteristic of the side chains such as basic, neutral or acid, or the presence or absence of steroid bulk. However, tumor necrosis factor as defined herein specifically excludes lymphotoxin, or TNF-beta, as well as glycosylated TNF of other species such as murine TNF-alpha.

20       A significant factor in establishing the identity of a polypeptide as glycosylated TNF is the ability of antisera which are capable of substantially neutralizing the cytolytic activity of mature glycosylated TNF to also substantially neutralize the cytolytic activity of the polypeptide in question. However, it should be recognized that immunological identity and cytotoxic identity are not necessarily coextensive.

25       Glycosylated tumor necrosis factor as defined herein includes, for example, TNF derivatives like insertion mutants, deletion mutants, or fusion proteins described above. These derivatives will bring glycosylated TNF outside of the

molecular weight established for native human glycosylated TNF. Similarly, glycosylated TNF may be engineered in order to reduce or eliminate susceptibility to hydrolysis by trypsin or other proteases.

The language "capable" of cytotoxic activity for *in vivo* tumor necrosis means that the term tumor necrosis factor includes polypeptides which can be converted, as by enzymatic hydrolysis, from an inactive state analogous to a zymogen to a polypeptide fragment which exhibits the desired biological activity. Typically, inactive precursors will be fusion proteins in which mature glycosylated TNF is linked by a peptide bond at its carbonyl terminus to a human protein or fragment thereof. The sequence at this peptide bond or nearby is selected so as to be susceptible to proteolytic hydrolysis to release glycosylated TNF, either *in vivo* or, as part of a manufacturing protocol, *in vitro*. The glycosylated TNF factor that is so generated then will exhibit the definitionally-required cytotoxic activity.

Mutant glycosylated TNF derivatives include the predetermined, i.e., site-specific, mutations of glycosylated TNF or its fragments. The objective of mutagenesis is to construct DNA that encodes glycosylated TNF as defined above, i.e., glycosylated TNF which exhibits cytotoxic activity towards tumor cells *in vitro* or acts like glycosylated TNF *in vivo*, and which retains residual homology with glycosylated TNF, but which also exhibits improved properties and activity. Mutant glycosylated tumor necrosis factor is defined as a polypeptide otherwise falling within the homology definition for glycosylated tumor necrosis factor set forth herein but which has an amino acid sequence different from that of glycosylated TNF whether by way of deletion, substitution, or insertion. For example, the lysine or arginine residues of glycosylated TNF may be mutated to histidine or another amino acid residue which does not render the protein proteolytically labile. Similarly, cysteine could be replaced by other residues and cross-linked chemically in order to confer oxidative stability. It is not necessary that mutants meet the activity requirements for glycosylated TNF, for

95  
94  
93  
92  
91  
90  
89  
88  
87  
86  
85  
84  
83  
82  
81  
80  
79  
78  
77  
76  
75  
74  
73  
72  
71  
70  
69  
68  
67  
66  
65  
64  
63  
62  
61  
60  
59  
58  
57  
56  
55  
54  
53  
52  
51  
50  
49  
48  
47  
46  
45  
44  
43  
42  
41  
40  
39  
38  
37  
36  
35  
34  
33  
32  
31  
30  
29  
28  
27  
26  
25  
24  
23  
22  
21  
20  
19  
18  
17  
16  
15  
14  
13  
12  
11  
10  
9  
8  
7  
6  
5  
4  
3  
2  
1

even biologically inactive mutants will be useful upon labeling or immobilization as reagents in immunoassays. However, in this case the mutants will retain at least one epitopic site which is cross-reactive with antibody to glycosylated TNF.

5       Mutations in DNA which encode the glycosylated TNF are not necessarily expressed in the final secreted product. For example, a major class of DNA substitution mutations are those in which a different secretory leader or signal has been substituted for the native human secretory leader, either by deletions within the leader sequence or by substitutions, wherein most or all of the native leader is exchanged for a leader more likely to be recognized by the CHO cells. When the 10 secretory leader is "recognized" by the host CHO cells, the fusion protein consisting of glycosylated TNF and the leader ordinarily is cleaved at the leader-glycosylated TNF peptide bond in the events that lead to secretion of the glycosylated TNF.

15       Another major class of DNA mutants that are not expressed as glycosylated TNF derivatives are nucleotide substitutions made to enhance expression, primarily to avoid amino terminal loops in the transcribed mRNA or to provide codons that are more readily transcribed by the CHO, e.g., the well-known CHO preference codons for CHO expression.

20       Having now fully described this invention, it will be appreciated by those skilled in the art that the same can be performed within a wide range of equivalent parameters, concentrations, and conditions without departing from the spirit and scope 25 of the invention and without undue experimentation.

      While this invention has been described in connection with specific embodiments thereof, it will be understood that it is capable of further modifications. This application is intended to cover any variations, uses, or adaptations of the 25 inventions following, in general, the principles of the invention and including such departures from the present disclosure as come within known or customary practice

04925405 00000000

within the art to which the invention pertains and as may be applied to the essential features hereinbefore set forth as follows in the scope of the appended claims.

All references cited herein, including journal articles or abstracts, published or corresponding U.S. or foreign patent applications, issued U.S. or foreign 5 patents, or any other references, are entirely incorporated by reference herein, including all data, tables, figures, and text presented in the cited references.

Additionally, the entire contents of the references cited within the references cited herein are also entirely incorporated by reference.

Reference to known method steps, conventional methods steps, known 10 methods or conventional methods is not in any way an admission that any aspect, description or embodiment of the present invention is disclosed, taught or suggested in the relevant art.

The foregoing description of the specific embodiments will so fully reveal the general nature of the invention that others can, by applying knowledge 15 within the skill of the art (including the contents of the references cited herein), readily modify and/or adapt for various applications such specific embodiments, without undue experimentation, without departing from the general concept of the present invention. Therefore, such adaptations and modifications are intended to be within the meaning and range of equivalents of the disclosed embodiments, based on the teaching 20 and guidance presented herein. It is to be understood that the phraseology or terminology herein is for the purpose of description and not of limitation, such that the terminology or phraseology of the present specification is to be interpreted by the skilled artisan in light of the teachings and guidance presented herein, in combination with the knowledge of one of ordinary skill in the art.

References:

Aggarwal et al, 1987 Tumour necrosis factor and related cytotoxins. Wiley, Chichester (Ciba Foundation Symposium 131) p. 39-51 (1987)

Beutler et al, Nature, 320:584-588 (1986).

Beyaert et al, FEBS Letters, 340:9-16 (1994).

Fiers, FEBS, 285:199-212 (1991).

Korn et al, Lymphokine Res., 7:349-358 (1988)

Malik et al, Eur. J. Cancer, 26:1031-1034 (1990).

Markham et al, Eur. Cytokine Netw, 6:49-54 (1995)

Marmenout et al, Eur. J. Biochem, 152:512-522 (1985)

Old, Scientific American, 258:59-60, 69-75 (1988)

Porter, TIBTECH, 9:158-162 (1991).

Vilcek et al, J.Bio.Chem., 266:7313-7316 (1991).

Wallace et al, USP 4,879,226

Aggarwal et al, EP 0168214